transcripts at imatinib cessation were quantified by droplet digital PCR (ddPCR) for 175 patients on the STIM2 trial. Patients with transcripts below a defined cutoff had a 12-month molecular recurrence rate of 46% versus 68% for those above the cutoff. Implications of using ddPCR in forecasting successful imatinib cessation are discussed..
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858959 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-19-2270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.
Int J Mol Sci
November 2024
Department of Biopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Lodz, Poland.
Treatment options for pulmonary arterial hypertension (PAH) have improved substantially in the last 30 years, but there is still a need for novel molecules that can regulate the excessive accumulation of pulmonary artery smooth muscle cells (PASMCs) and consequent vascular remodeling. One set of possible candidates are protein kinases. The study provides an overview of existing preclinical and clinical data regarding small-molecule protein kinase inhibitors in PAH.
View Article and Find Full Text PDFHigh-Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib-Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.
Case Rep Hematol
November 2024
Department of Haematology, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, UK.
Article Synopsis
- The occurrence of both chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in a single patient is very uncommon, and there are only a handful of documented cases.
- The case described involves a patient with CML who successfully responded to treatment with imatinib, achieving a major molecular response.
- Later, the same patient developed CLL, which required the addition of ibrutinib to their treatment regimen.
Non-alkylating agents-induced gonadotoxicity in pre-pubertal males: Insights on the clinical and pre-clinical front.
Clin Transl Sci
November 2024
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Whilst chemotherapy regimens have proven to be more successful for pediatric cancer patients over the years, their influence on long-term side effects is relatively poorly understood. One of the possible targets is the gonads, with gonadotoxic agents representing those that threaten the patient's ability to have children post surviving the primary disease treatment. Many risk stratification guidelines have categorized these agents based on the severity of their effect on the pre-pubertal testis.
View Article and Find Full Text PDF[Rethinking several issues related to surgical treatment for advanced GIST in the era of targeted therapy].
Zhonghua Wei Chang Wai Ke Za Zhi
November 2024
Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai200127, China.
Article Synopsis
Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort.
Am J Hematol
November 2024
Tata Memorial Hospital, Pediatric Oncology, Mumbai, India.
Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%-3% of all childhood leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their long-term effects on growth and bone health in children. We prospectively studied treatment-free remission (TFR) in 45 children with pCML in chronic phase on imatinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!